#26 Pharmacotherapy for Smoking: What works and what to consider (PART I)?

CLINICAL QUESTION

QUESTION CLINIQUE

In patients ready to make a smoking cessation attempt, how effective are registered first-line medications and what are the potential concerns?

BOTTOM LINE

RÉSULTAT FINAL

There are four first-line options of nicotine replacement therapy (NRT) (gum, patch, lozenge or inhaler) and all improve the chance of abstinence from smoking. For every 17 patients treated with NRT, one will remain abstained from smoking at six months. Adverse events are low but supportive follow-up will allow monitoring and can improve cessation.

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session

EVIDENCE

DONNÉES PROBANTES

Part I reviews Nicotine Replacement Therapy (NRT) and related issues Part II discusses antidepressants and varenicline

NRT: Cochrane systematic review¹ of 150 randomized controlled trials (RCTs):
- Overall Risk Ratio (RR) of abstinence: 1.60 (1.53 to 1.68).
  - Gum: 1.49 (1.40 - 1.60, 55 trials).
  - Patch: 1.64 (1.52 - 1.78, 43 trials).
  - Inhaler: 1.90 (1.36 - 2.67, 4 trials).
  - Lozenge: 1.95 (1.61 - 2.73, 6 trials).
- Some evidence combining rapid-acting NRT with patch can offer small advantage over monotherapy: RR 1.34 (1.18-1.51, 9 trials).
- There is no difference in efficacy between NRT and bupropion: RR 1.01 (0.87- 1.18).
- Adverse events:
  - Local irritation relates to the type of product.
  - No evidence that NRT increases myocardial infarctions.
Assuming placebo cessation rates of 10% (mean across studies), the number needed to treat (NNT) for NRT therapy is approximately 17 (range 15-19).

Context:

Smoking cessation is the most effective preventive maneuver for conditions including COPD, cancer and cardiovascular disease.
- For example, an RCT² of aggressive smoking cessation intervention for 209 patients after CCU admission 2 years later resulted in:
  - 39% quitting versus 9%.
  - 3% mortality versus 12%, for a 9% absolute reduction (NNT 11).
  - For comparison, ASA provides a 1.4% reduction (NNT 72) in mortality in a similar population and time frame.³
Pharmacotherapy is safe and effective in a broad range of populations, including the mentally ill.
Combining counseling and support with pharmacotherapy improves outcomes.¹